BioMarin Announces Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $80 at Oppenheimer
October 24, 2019 7:02 AM EDTOppenheimer analyst Leland Gershell lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $80.00 (from $81.00) while maintaining a Perform rating.
The analyst commented, "BMRN's 3Q19 total product revenue of $451M was roughly in line with consensus of $448M, with lower R&D... More
BioMarin Pharma (BMRN) Tops Q3 Revenue
October 23, 2019 4:16 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.30, which may not compare to the analyst estimate of $0.06. Revenue for the quarter came in at $461.1 million versus the consensus estimate of $454.55 million.
Commenting on third quarter results, Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, said, "BioMarin is entering a stage that I believe will bring significant growth as we get closer to submitting marketing applications for valoctocogene roxaparvovec for severe hemophilia A and a pivotal data read-out for vosoritide for children with achondroplasia. These potential new products, combined with our strong base business... More
